Cidara Therapeutics Inc expected to post a loss of $2.00 a share - Earnings Preview

Cidara Therapeutics

05/08/2025 22:27

Cidara Therapeutics Inc CDTX.OQ CDTX.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

​LSEG's mean analyst estimate for Cidara Therapeutics Inc is for a loss of $2.00 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cidara Therapeutics Inc is $56.50, about 10.5% below its last closing price of $62.46

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-3.73
-3.54
-1.66
Beat
53.2
Dec. 31 2025
-3.52
-3.62
-5.37
Missed
-48.3
Sep. 30 2024
-3.55
-4.25
-2.45
Beat
42.4​
Jun. 30 2024
-4.01
-3.22
-1.39
Beat
56.9
​​Mar. 31 2024
-0.20
-0.20
-2.28
Missed
-1,040
Dec. 31 2023
-2.07
-0.80
Beat
61.3​
Sep. 30 2023
-3.19
-3.25
-1.80
Beat
44.6
Jun. 30 2023
-2.04
-2.60
-2.80
Missed
-7.7

This summary was machine generated August 5 at 21:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)